A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with Hematologic Malignancies
This clinical research study has 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the best dose of APG-2575 that can be given to patients with relapsed (has come back) or refractory (has stopped responding to treatment) acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL). The goal of Part 2 of this clinical research study is to learn if the dose of APG-2575 found in Part 1 can help to control AML/CLL. The safety and tolerability of this drug will also be studied in both parts of the study. This is the first study using APG-2575 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: APG-2575
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Ascentage Pharma Group Inc.
IRB Review and Approval Date: 11/08/2018
Recruitment Status: Open
Projected Accrual: up to 90
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: